St common primary malignant bone tumor that occurs in children and young adults [1]. These tumors are characterized by a highly 
malignant and metastatic potential [2]. Despite aggressive chemotherapeutic treatment strategies, the rapid development of metastatic lesions and resistance to chemotherapy remain the major mechanisms responsible for the failure of treatments and poor survival rate of patients, which points to the need for new effective therapeutic strategies to prevent cell metastasis. The molecular mechanisms that are involved in osteosarcoma growth and metastasis are not fully understood. A number of studies have suggested a role of 
Wnt signaling, an important pathway that controls osteoblastogenesis. Binding of canonical Wnts to frizzled (Fz) receptor and low-density lipoprotein 5 or 6 (LRP5/6) co-receptors leads to inhibition of Sapropterin (dihydrochloride) web b-catenin phosphorylation and subsequent translocation into the nucleus where 1326631 it interacts with TCF/LEF transcription factors to activate the expression of Wnt-responsive genes [3]. Wnt signaling increases osteoprogenitor cell proliferation and their progression along theosteogenic lineage and prevents apoptosis in more mature osteoblasts [4,5,6]. A role of Wnt signaling in osteosarcoma development is supported by the finding that several Wnt ligands, receptors and co-receptors are highly expressed while Wnt inhibitors are downregulated in osteosarcoma cells [7]. It was also shown that the Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and its disruption accelerates osteosarcoma development in mice [8]. Increased b-cateninmediated activity has been frequently reported in osteosarcoma [9,10,11], further supporting a role for Wnt signaling in osteosarcoma development. The transcriptional cofactor LIM-only protein FHL2 (four and a half LIM domains protein 2) is a multifunctional adaptor protein that is involved in the regulation of signal transduction, gene expression, cell proliferation and differentiation [12,13]. The role of FHL2 in the development of cancers is complex. FHL2 was found to be down-regulated in some cancers and to be elevated in others compared to normal tissues, suggesting that FHL2 may act as an oncoprotein or a tumor Vasopressin suppressor, depending on its role as transcriptional activator or repressor in the cell type in which it isFHL2 Silencing Reduces Osteosarcoma Tumorigenesisexpressed [13]. One mechanism by which FHL2 may be linked to tumorigenesis is an interaction with key regulatory molecules. In muscle cells for example, FHL2 interacts with b-catenin and represses b-catenin-dependent transcription [14]. In contrast, in hepatoblastoma cells, FHL2 activates b-catenin-dependent transcription [15]. In bone, FHL2 was found to promote osteoblast differentiation [16,17,18]. We previously showed that FHL2 acts as an endogenous activator of mesenchymal cell differentiation into osteoblasts through its interaction with b-catenin and activation of Wnt/b-catenin signaling [19]. In these cells, overexpression of FHL2 increased Wnt/b-catenin signaling and osteogenic differentiation [19]. However, the implication of FHL2 in primary bone cancer progression and tumorigenesis has not been investigated. In this study, we used a shRNA-based technique to study the contribution of FHL2 in primary bone tumor cell growth, invasion and migration, and we used xenograft experiments in mice to analyse the impact of FHL2 on tumorigenesis in vivo. Our data indicate that FHL2 silencing.St common primary malignant bone tumor that occurs in children and young adults [1]. These tumors are characterized by a highly malignant and metastatic potential [2]. Despite aggressive chemotherapeutic treatment strategies, the rapid development of metastatic lesions and resistance to chemotherapy remain the major mechanisms responsible for the failure of treatments and poor survival rate of patients, which points to the need for new effective therapeutic strategies to prevent cell metastasis. The molecular mechanisms that are involved in osteosarcoma growth and metastasis are not fully understood. A number of studies have suggested a role of Wnt signaling, an important pathway that controls osteoblastogenesis. Binding of canonical Wnts to frizzled (Fz) receptor and low-density lipoprotein 5 or 6 (LRP5/6) co-receptors leads to inhibition of b-catenin phosphorylation and subsequent translocation into the nucleus where 1326631 it interacts with TCF/LEF transcription factors to activate the expression of Wnt-responsive genes [3]. Wnt signaling increases osteoprogenitor cell proliferation and their progression along theosteogenic lineage and prevents apoptosis in more mature osteoblasts [4,5,6]. A role of Wnt signaling in osteosarcoma development is supported by the finding that several Wnt ligands, receptors and co-receptors are highly expressed while Wnt inhibitors are downregulated in osteosarcoma cells [7]. It was also shown that the Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and its disruption accelerates osteosarcoma development in mice [8]. Increased b-cateninmediated activity has been frequently reported in osteosarcoma [9,10,11], further supporting a role for Wnt signaling in osteosarcoma development. The transcriptional cofactor LIM-only protein FHL2 (four and a half LIM domains protein 2) is a multifunctional adaptor protein that is involved in the regulation of signal transduction, gene expression, cell proliferation and differentiation [12,13]. The role of FHL2 in the development of cancers is complex. FHL2 was found to be down-regulated in some cancers and to be elevated in others compared to normal tissues, suggesting that FHL2 may act as an oncoprotein or a tumor suppressor, depending on its role as transcriptional activator or repressor in the cell type in which it isFHL2 Silencing Reduces Osteosarcoma Tumorigenesisexpressed [13]. One mechanism by which FHL2 may be linked to tumorigenesis is an interaction with key regulatory molecules. In muscle cells for example, FHL2 interacts with b-catenin and represses b-catenin-dependent transcription [14]. In contrast, in hepatoblastoma cells, FHL2 activates b-catenin-dependent transcription [15]. In bone, FHL2 was found to promote osteoblast differentiation [16,17,18]. We previously showed that FHL2 acts as an endogenous activator of mesenchymal cell differentiation into osteoblasts through its interaction with b-catenin and activation of Wnt/b-catenin signaling [19]. In these cells, overexpression of FHL2 increased Wnt/b-catenin signaling and osteogenic differentiation [19]. However, the implication of FHL2 in primary bone cancer progression and tumorigenesis has not been investigated. In this study, we used a shRNA-based technique to study the contribution of FHL2 in primary bone tumor cell growth, invasion and migration, and we used xenograft experiments in mice to analyse the impact of FHL2 on tumorigenesis in vivo. Our data indicate that FHL2 silencing.
